In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell–Mediated Tumor Killing-Reference-Cited by-同舟云学术

In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell–Mediated Tumor Killing

Published:2016-04-26 Issue:17 Volume:22 Page:4417-4427
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Lehmann Steffi,Perera Ramanil,Grimm Hans-Peter,Sam Johannes,Colombetti Sara,Fauti Tanja,Fahrni Linda,Schaller Teilo,Freimoser-Grundschober Anne,Zielonka Jörg,Stoma Szymon,Rudin Markus,Klein Christian,Umana Pablo,Gerdes Christian,Bacac Marina

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials;Nature Communications;2024-05-15

2. Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances;Journal of Controlled Release;2024-04

3. End-to-end approach for the characterization and control of product-related impurities in T cell bispecific antibody preparations;International Journal of Pharmaceutics: X;2023-12

4. Asymmetric anti-CLL-1×CD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release;Journal for ImmunoTherapy of Cancer;2023-10

5. Using quantitative systems pharmacology modeling to optimize combination therapy of anti-PD-L1 checkpoint inhibitor and T cell engager;Frontiers in Pharmacology;2023-06-20